February 3, 2014


United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549


Attention:   Jeffrey P. Riedler, Assistant Director
       Christina De Rosa
       James Peklenk
       Andrew Mew


Re:   Eleven Biotherapeutics, Inc.
       Registration Statement on Form S-1 (File No. 333-193131)


Ladies and Gentlemen:


In connection with the above-captioned Registration Statement, we wish to advise that between January 23, 2014 and the date hereof, approximately 1,660 copies of the Preliminary Prospectus dated January 23, 2014 were distributed to prospective underwriters, institutional investors and prospective dealers.


We have been informed by the participating underwriters that they have complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.


We hereby join in the request of the registrant that the effectiveness of the above-captioned Registration Statement, as amended, be accelerated to 4:00 p.m. Eastern Standard Time, on Wednesday, February 5, 2014 or as soon thereafter as practicable.




[signature page follows]

Very truly yours,


Citigroup Global Markets Inc.

Cowen and Company, LLC

Leerink Partners LLC

As representatives of the

Prospective Underwriters

By:   Citigroup Global Markets Inc.
By:   /s/ Christopher Gartin

Name: Christopher Gartin

Title: Vice President

By:   Cowen and Company, LLC
By:   /s/ Jason Fenton

Name: Jason Fenton

Title: Managing Director

By:   Leerink Partners LLC
By:   /s/ Anthony Gibney

Name: Anthony Gibney

Title: Managing Director